Articles by tag: in-vivo-therapy

In vivo gene editing: CRISPR therapy for hereditary angioedema

Single-dose CRISPR therapy NTLA-2002 reduced hereditary angioedema attacks by 87% in phase III. Learn how this will change treatment and pave the way to a cure.